Safety Profile
Tesamorelin Side Effects & Safety
Tesamorelin is FDA approved for HIV-associated lipodystrophy with safety data from two Phase III trials.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Side effects by severity
Injection site reactions
25%Redness, itching, mild pain.
Arthralgia
13%Joint pain related to fluid retention.
Pain in extremity
Related to edema.
Edema
Peripheral fluid retention.
Myalgia
Muscle pain; typically mild.
Carpal tunnel syndrome
Due to fluid retention.
Hyperglycemia
GH-mediated counter-regulation of insulin; monitor glucose.
Hypersensitivity reactions
Rare angioedema reported.
Pancreatitis
Rarely reported; causality uncertain.
Contraindications
- Disruption of hypothalamic-pituitary axis (pituitary tumor, surgery, radiation)
- Active malignancy
- Pregnancy
- Hypersensitivity
Drug interactions
- Insulin and oral hypoglycemics — may require dose adjustment
- Glucocorticoids — blunt GH response
Special populations
Not recommended in pregnancy. Limited pediatric data. Elderly data limited.
Safety summary
Tesamorelin has a well-characterized safety profile from its FDA trials. The primary safety consideration is glucose tolerance, particularly in patients with pre-diabetes or diabetes.
Frequently asked
Does tesamorelin raise blood sugar?
Yes — modest increases in fasting glucose and HbA1c occur. Patients with diabetes may need medication adjustment; monitor glucose regularly.